JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence

Marta Kacprzyk; Magdalena Masajada; Aleksandra Kulbat; Karolina Richter; Paweł Brzewski; Wojciech M. Wysocki

doi:10.5114/dr.2025.158596

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

5/2025
vol. 112

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Artykuł przeglądowy

JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence

Marta Kacprzyk

¹

,

Magdalena Masajada

^{1, 2}

,

Aleksandra Kulbat

^{3, 4, 5}

,

Karolina Richter

^{3, 6}

,

Paweł Brzewski

^{1, 2}

,

Wojciech M. Wysocki

^{3, 4, 5}

Department of Dermatology and Venereology, Stefan Zeromski Municipal Hospital, Krakow, Poland
Chair of Dermatology and Venereology, Faculty of Medicine, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
Chair of Surgery, Faculty of Medicine, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
Department of Oncological Surgery, 5th Military Clinical Hospital, Krakow, Poland
National Institute of Oncology, Maria Sk³odowska-Curie Memorial, Warsaw, Poland
Department of General, Oncological, Metabolic and Emergency Surgery, University Hospital, Krakow, Poland

Dermatol Rev/Przegl Dermatol 2025, 112, 306-313

DOI: https://doi.org/10.5114/dr.2025.158596

Data publikacji online: 2025/12/30

Pełna treść artykułu Pobierz cytowanie

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Kacprzyk M, Masajada M, Kulbat A, Richter K, Brzewski P, Wysocki W. JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence. Dermatology Review/Przegląd Dermatologiczny. 2025;112(5):306-313. doi:10.5114/dr.2025.158596.

APA

Kacprzyk, M., Masajada, M., Kulbat, A., Richter, K., Brzewski, P.,  & Wysocki, W. (2025). JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence. Dermatology Review/Przegląd Dermatologiczny, 112(5), 306-313. https://doi.org/10.5114/dr.2025.158596

Chicago

Kacprzyk, Marta, Magdalena Masajada, Aleksandra Kulbat, Karolina Richter, Paweł Brzewski,  and Wojciech M. Wysocki. 2025. "JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence". Dermatology Review/Przegląd Dermatologiczny 112 (5): 306-313. doi:10.5114/dr.2025.158596.

Harvard

Kacprzyk, M., Masajada, M., Kulbat, A., Richter, K., Brzewski, P.,  and Wysocki, W. (2025). JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence. Dermatology Review/Przegląd Dermatologiczny, 112(5), pp.306-313. https://doi.org/10.5114/dr.2025.158596

MLA

Kacprzyk, Marta et al. "JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence." Dermatology Review/Przegląd Dermatologiczny, vol. 112, no. 5, 2025, pp. 306-313. doi:10.5114/dr.2025.158596.

Vancouver

Kacprzyk M, Masajada M, Kulbat A, Richter K, Brzewski P, Wysocki W. JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence. Dermatology Review/Przegląd Dermatologiczny. 2025;112(5):306-313. doi:10.5114/dr.2025.158596.

Metryki PlumX:

Psoriasis and psoriatic arthritis are chronic immune-mediated disorders associated with substantially impaired quality of life and comorbidities. Janus kinase (JAK) inhibitors have recently emerged as highly efficient therapeutic agents for the treatment of various inflammatory and hematologic diseases. Nevertheless, there are some concerns about potentially increased risks of infections and therapy-induced malignancies associated with utilization of JAK inhibitors. In this study, we review the current knowledge about the role of particular components of the JAK/STAT pathway in the carcinogenesis and explore the evidence on the safety of JAK inhibitors in relation to the risk of melanoma and non-melanoma skin cancer in patients with psoriasis and psoriatic arthritis.

Indeks osobowy

JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis and the Risk of Skin Malignancies: a Review of Current Evidence

Marta Kacprzyk 1 , Magdalena Masajada 1, 2 , Aleksandra Kulbat 3, 4, 5 , Karolina Richter 3, 6 , Paweł Brzewski 1, 2 , Wojciech M. Wysocki 3, 4, 5

Marta Kacprzyk

¹

,

Magdalena Masajada

^{1, 2}

,

Aleksandra Kulbat

^{3, 4, 5}

,

Karolina Richter

^{3, 6}

,

Paweł Brzewski

^{1, 2}

,

Wojciech M. Wysocki

^{3, 4, 5}